*UPDATE ON CLINICAL TRIAL MILESTONE - CYTOMED THERAPEUTICS ACHIEVES COMPLETION OF DOSE LEVEL 1 OF ITS ANGELICA TRIAL, AND PROCEEDING TO DOSE LEVEL 2 IN PATIENTS WITH ADVANCED SOLID TUMORS OR HAEMATOLOGICAL MALIGNANCIES
*CYTOMED THERAPEUTICS LTD - TO START DOSE LEVEL 2 IN ANGELICA TRIAL Q3 2025
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 21-JUL-202514:01:10.093 GMT